logo
Share SHARE
FONT-SIZE Plus   Neg

Bristol-Myers, Meso Scale To Develop Diagnostic Assays For Alzheimer's Disease

Bristol-Myers Squibb Co. (BMY) and Meso Scale Discovery announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer's disease research.

As per the terms of the agreement, the companies will develop these assays based on the Meso Scale Discovery MULTI-ARRAY technology platform. Meso Scale Discovery will commercialize the assays for Alzheimer's disease research and drug development, and plans to release the assays in the second quarter of 2012. Terms of the agreement were not disclosed.

Alzheimer's disease is a progressive brain disease that impairs memory, interferes with thinking and ultimately destroys the ability of an individual to carry out simple tasks. The disease is a continuum, with damage to the brain starting long before the onset of dementia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
At Home Group Inc., the home décor retail store with 115 stores in 29 states is planning to go public. The pricing of initial public offering is expected in a range of $14 to $16 per share. The company in a filing with the SEC said it has got the approval to list the shares on the NYSE under symbol "HOME." McDonald's Corp. has suspended sales of Big Macs in Venezuela as the fast food chain is unable to source buns - one of the key components of a burger. Venezuela is suffering from food shortages recently due to an ongoing economic and political crisis. Telecom giant Verizon Communications Inc. has agreed to acquire the operating business of struggling Internet company Yahoo Inc. for about $4.83 billion in cash, the two companies said Monday. The transaction is expected to close in the first quarter of 2017.
comments powered by Disqus
Follow RTT